Author:
Stadler Simone,Weina Kasia,Gebhardt Christoffer,Utikal Jochen
Reference53 articles.
1. Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”;Pflugfelder;J Dtsch Dermatol Ges,2013
2. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011
3. Phase II trial (BREAK-2) of the braf inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma;Ascierto;J Clin Oncol,2013
4. Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E;Hallmeyer;J Clin Oncol,2014
5. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management;Manousaridis;J Eur Acad Dermatol Venereol,2013
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献